Table 1 Statistical optimization of the HA-REG-CAP-CUBs formulation via design Expert®.

From: Hyaluronic acid capped cubosomes co-loaded with antitumor agents towards the treatment of colorectal cancer

Run

Factor 1

Factor 2

Factor 3

Response 1

Response 2

Response 3

Response 4

Response 5

GMO (mg)

Tween 80 (mg)

CAP (mg)

Particle size (nm)

PDI

Zeta potential (mV)

%EE (REG)

%EE (CAP)

01

200

30

5

244.1 ± 2.4

0.239 ± 0.03

−34.2 ± 3.1

82.47 ± 1.3

75.39 ± 2.1

02

150

40

5

187.4 ± 3.1

0.147 ± 0.01

−16.3 ± 2.5

72.48 ± 1.2

64.38 ± 1.6

03

200

40

10

234.7 ± 4.3

0.256 ± 0.01

−28.2 ± 4.5

80.66 ± 1.4

83.57 ± 1.2

04

100

40

10

156.4 ± 5.2

0.167 ± 0.02

−10.9 ± 2.3

63.01 ± 0.9

65.44 ± 2.2

05

200

20

10

252.3 ± 2.4

0.227 ± 0.03

−38.1 ± 3.4

81.47 ± 1.1

82.35 ± 1.5

06

150

30

10

199.4 ± 2.5

0.269 ± 0.01

−24.2 ± 3.7

74.59 ± 1.5

73.66 ± 1.7

07

100

30

15

183.6 ± 3.7

0.186 ± 0.02

−12.7 ± 3.1

59.36 ± 1.3

69.38 ± 1.3

08

150

40

15

213.1 ± 2.6

0.177 ± 0.02

−20.4 ± 4.8

71.49 ± 1.6

76.28 ± 2.3

09

150

30

10

196.1 ± 1.4

0.231 ± 0.03

−25.5 ± 5.2

78.56 ± 2.1

76.48 ± 2.5

10

150

20

15

215.3 ± 3.2

0.326 ± 0.02

−19.7 ± 3.3

72.33 ± 2.3

78.69 ± 1.9

11

200

30

15

258.1 ± 4.2

0.247 ± 0.01

−32.8 ± 2.3

80.46 ± 0.6

84.69 ± 0.8

12

150

30

10

198.6 ± 5.5

0.251 ± 0.02

−26.1 ± 1.8

76.39 ± 1.3

78.81 ± 1.4

13

100

20

10

176.7 ± 4.6

0.269 ± 0.04

−18.3 ± 2.5

64.68 ± 1.6

67.58 ± 2.3

14

100

30

5

173.6 ± 2.8

0.167 ± 0.05

−9.78 ± 1.3

61.89 ± 1.1

59.08 ± 1.5

15

150

20

5

210.4 ± 3.9

0.273 ± 0.04

−18.9 ± 1.7

73.97 ± 1.9

71.49 ± 1.7

  1. GMO: Glyceryl mono-oleate, CAP: Capecitabine, REG: Regorafenib, PDI: Polydispersity index, %EE: Percent entrapment efficiency.